JP2008514223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514223A5 JP2008514223A5 JP2007534174A JP2007534174A JP2008514223A5 JP 2008514223 A5 JP2008514223 A5 JP 2008514223A5 JP 2007534174 A JP2007534174 A JP 2007534174A JP 2007534174 A JP2007534174 A JP 2007534174A JP 2008514223 A5 JP2008514223 A5 JP 2008514223A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- present
- compound
- strand
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108091028664 Ribonucleotide Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002336 ribonucleotide Substances 0.000 claims 5
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 108091081021 Sense strand Proteins 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 208000012998 acute renal failure Diseases 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 231100000895 deafness Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61399104P | 2004-09-28 | 2004-09-28 | |
| US60/613,991 | 2004-09-28 | ||
| US65819605P | 2005-03-02 | 2005-03-02 | |
| US60/658,196 | 2005-03-02 | ||
| US70302005P | 2005-07-26 | 2005-07-26 | |
| US60/703,020 | 2005-07-26 | ||
| PCT/IL2005/001035 WO2006035434A2 (en) | 2004-09-28 | 2005-09-27 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012049015A Division JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008514223A JP2008514223A (ja) | 2008-05-08 |
| JP2008514223A5 true JP2008514223A5 (enExample) | 2008-10-30 |
| JP4991547B2 JP4991547B2 (ja) | 2012-08-01 |
Family
ID=36119277
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534174A Expired - Fee Related JP4991547B2 (ja) | 2004-09-28 | 2005-09-27 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| JP2012049015A Withdrawn JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| JP2014147235A Expired - Fee Related JP5952350B2 (ja) | 2004-09-28 | 2014-07-17 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012049015A Withdrawn JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| JP2014147235A Expired - Fee Related JP5952350B2 (ja) | 2004-09-28 | 2014-07-17 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8765699B2 (enExample) |
| EP (1) | EP1799269B1 (enExample) |
| JP (3) | JP4991547B2 (enExample) |
| KR (2) | KR101409241B1 (enExample) |
| CN (1) | CN102643818B (enExample) |
| AU (1) | AU2005288522B2 (enExample) |
| BR (1) | BRPI0516177B8 (enExample) |
| CA (1) | CA2580126C (enExample) |
| DK (1) | DK1799269T3 (enExample) |
| ES (1) | ES2594083T3 (enExample) |
| HU (1) | HUE030844T2 (enExample) |
| LT (1) | LT1799269T (enExample) |
| MX (2) | MX2007003795A (enExample) |
| NZ (1) | NZ553987A (enExample) |
| PL (1) | PL1799269T3 (enExample) |
| PT (1) | PT1799269T (enExample) |
| RU (1) | RU2584609C2 (enExample) |
| SG (1) | SG161307A1 (enExample) |
| WO (1) | WO2006035434A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040219569A1 (en) * | 1999-07-06 | 2004-11-04 | Fruma Yehiely | Gene identification method |
| AU2001264317A1 (en) * | 2000-06-20 | 2002-01-02 | Koken Co., Ltd. | Preparations for oligonucleotide transfer |
| DE60232149D1 (de) * | 2001-06-20 | 2009-06-10 | Dainippon Sumitomo Pharma Co | Verfahren zur förderung des nukleinsäuretransfers |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2005099772A2 (en) * | 2004-04-13 | 2005-10-27 | Boston Biomedical Research Institute | Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| KR100939274B1 (ko) | 2004-08-16 | 2010-01-29 | 쿠아크 파마수티칼스 인코퍼레이티드 | 알티피801 억제제의 치료적 용도 |
| JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| JP4131271B2 (ja) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | 情報処理装置および方法、並びにプログラム |
| US20070135368A1 (en) * | 2005-12-09 | 2007-06-14 | Knapp Pamela E | Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| WO2008041933A2 (en) * | 2006-10-02 | 2008-04-10 | Aprea Ab | Rna interference against wrap53 to treat hyperproliferative diseases |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| DE102007008596B4 (de) * | 2007-02-15 | 2010-09-02 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung |
| US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| WO2008126085A2 (en) * | 2007-04-12 | 2008-10-23 | Quark Pharmaceuticals, Inc. | Method for treating bone marrow disorders |
| EP3199635B1 (en) | 2007-05-11 | 2019-02-06 | Adynxx, Inc. | Gene expression and pain |
| WO2009001359A2 (en) * | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| CA2701845A1 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
| US8431692B2 (en) * | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
| JP2012517815A (ja) * | 2009-02-18 | 2012-08-09 | サイレンス・セラピューティクス・アーゲー | Ａｎｇ２の発現を阻害するための手段 |
| US8637482B2 (en) | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| CN102792161B (zh) * | 2009-08-28 | 2014-11-12 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后的方法及组合物 |
| EP3252068B1 (en) | 2009-10-12 | 2025-07-02 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| EP2649181B1 (en) * | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| EP2699271A4 (en) | 2011-04-20 | 2015-10-07 | Larry J Smith | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| CN103145845A (zh) * | 2011-12-06 | 2013-06-12 | 吉林圣元科技有限责任公司 | Tat与人野生型P53融合蛋白在毕赤酵母中的表达 |
| RU2667960C2 (ru) | 2012-04-18 | 2018-09-25 | Ногра Фарма Лимитед | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации |
| CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
| SI3444349T1 (sl) * | 2014-05-29 | 2021-07-30 | Quark Pharmaceuticals, Inc. | Postopki in sestavki za preprečevanje ishemične reperfuzijske poškodbe v organih |
| CA2957250A1 (en) | 2014-08-15 | 2016-02-18 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US12091664B2 (en) | 2018-01-12 | 2024-09-17 | University Of Massachusetts | Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2463774A1 (fr) | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| CA2028756A1 (en) | 1989-11-24 | 1991-05-25 | Alfons H. M. Raeymaekers | Immunostimulating 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole derivatives |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ，インコーポレイテッド | 改変ヌクレオシド間結合 |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| GB9608937D0 (en) * | 1996-04-29 | 1996-07-03 | Cancer Res Campaign Tech | Screening methods for therapeutics and peptides used in the screen |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5849774A (en) * | 1996-07-03 | 1998-12-15 | University Of Pittsburgh | Treatment of sepsis-induced acute renal failure |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999055910A1 (en) | 1998-04-24 | 1999-11-04 | Arizona Board Of Regents | Method of inducing apoptosis in a target cell |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| AU2156600A (en) * | 1998-11-25 | 2000-06-13 | Cold Spring Harbor Laboratory | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| WO2000044364A2 (en) | 1999-01-29 | 2000-08-03 | The Board Of Trustees Of The University Of Illinois | P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
| WO2001068336A2 (en) | 2000-03-16 | 2001-09-20 | Generis Gmbh | Method for manufacturing a structural part by a deposition technique |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
| US20040209832A1 (en) * | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| EP2221377B2 (en) * | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| WO2004019900A1 (en) * | 2002-08-27 | 2004-03-11 | Societe Des Produits Nestle | Preventing or treating epithelial tissue damage or hair loss |
| EP1560840B1 (en) | 2002-11-05 | 2015-05-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| AU2004248136B2 (en) | 2003-06-02 | 2011-09-15 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
| WO2005062937A2 (en) | 2003-12-22 | 2005-07-14 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna |
| CA2565701A1 (en) * | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| CA2568735A1 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| US7428919B2 (en) * | 2004-08-02 | 2008-09-30 | Young David P | Method and system for evaluating fluid flow through a heat exchanger |
| KR100939274B1 (ko) | 2004-08-16 | 2010-01-29 | 쿠아크 파마수티칼스 인코퍼레이티드 | 알티피801 억제제의 치료적 용도 |
| JP4991547B2 (ja) | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
| US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
-
2005
- 2005-09-27 JP JP2007534174A patent/JP4991547B2/ja not_active Expired - Fee Related
- 2005-09-27 MX MX2007003795A patent/MX2007003795A/es active IP Right Grant
- 2005-09-27 WO PCT/IL2005/001035 patent/WO2006035434A2/en not_active Ceased
- 2005-09-27 EP EP05788492.6A patent/EP1799269B1/en not_active Expired - Lifetime
- 2005-09-27 LT LTEP05788492.6T patent/LT1799269T/lt unknown
- 2005-09-27 PT PT57884926T patent/PT1799269T/pt unknown
- 2005-09-27 KR KR1020127033760A patent/KR101409241B1/ko not_active Expired - Fee Related
- 2005-09-27 CN CN201210097746.XA patent/CN102643818B/zh not_active Expired - Fee Related
- 2005-09-27 BR BRPI0516177A patent/BRPI0516177B8/pt not_active IP Right Cessation
- 2005-09-27 KR KR1020077009173A patent/KR101357016B1/ko not_active Expired - Fee Related
- 2005-09-27 NZ NZ553987A patent/NZ553987A/en not_active IP Right Cessation
- 2005-09-27 DK DK05788492.6T patent/DK1799269T3/en active
- 2005-09-27 PL PL05788492T patent/PL1799269T3/pl unknown
- 2005-09-27 CA CA2580126A patent/CA2580126C/en not_active Expired - Fee Related
- 2005-09-27 ES ES05788492.6T patent/ES2594083T3/es active Active
- 2005-09-27 AU AU2005288522A patent/AU2005288522B2/en not_active Ceased
- 2005-09-27 US US11/237,598 patent/US8765699B2/en active Active
- 2005-09-27 HU HUE05788492A patent/HUE030844T2/en unknown
- 2005-09-27 SG SG201002811-6A patent/SG161307A1/en unknown
- 2005-09-27 RU RU2011130434/10A patent/RU2584609C2/ru active
-
2007
- 2007-03-28 MX MX2012001488A patent/MX336710B/es unknown
- 2007-07-10 US US11/827,199 patent/US7842674B2/en active Active
-
2008
- 2008-01-11 US US12/008,578 patent/US8148342B2/en not_active Expired - Fee Related
-
2012
- 2012-01-17 US US13/351,923 patent/US9006196B2/en not_active Expired - Fee Related
- 2012-03-06 JP JP2012049015A patent/JP2012152216A/ja not_active Withdrawn
-
2014
- 2014-07-01 US US14/321,484 patent/US9334499B2/en not_active Expired - Fee Related
- 2014-07-17 JP JP2014147235A patent/JP5952350B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514223A5 (enExample) | ||
| JP2022031772A5 (enExample) | ||
| JP5355856B2 (ja) | Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用 | |
| Veien et al. | Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study | |
| AU2014244083B2 (en) | Methods for modulating chemotherapeutic cytotoxicity | |
| TWI702045B (zh) | 治療甲狀腺素運載蛋白（ｔｔｒ）調節之澱粉樣變性的方法 | |
| RU2011130434A (ru) | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний | |
| EP2609920A1 (en) | Method of treating cancer by a combined therapy of YM-155 with other anticancer agents | |
| Peirce et al. | Selective A2A adenosine receptor activation reduces skin pressure ulcer formation and inflammation | |
| JP2008510019A5 (enExample) | ||
| Smith et al. | Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime | |
| Bai et al. | Tongxinluo improves cardiac function and ameliorates ventricular remodeling in mice model of myocardial infarction through enhancing angiogenesis | |
| Paton | Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| JP2016506240A5 (enExample) | ||
| JP2020055884A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| US10023862B2 (en) | Organic compositions to treat beta-catenin-related diseases | |
| IL308752B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| CN105358150A (zh) | 用于心脏病的bet抑制疗法 | |
| WO2010107508A1 (en) | Inhibiting gsnor | |
| US20190071670A1 (en) | Methods Of Treatment For Alpha-1 Antitrypsin Deficiency | |
| EP2656850B1 (en) | Oligonucleotides for the treatment or alleviation of edema | |
| WO2016205631A1 (en) | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders | |
| AU2018314236A1 (en) | RNA aptamers against transferrin receptor (TfR) |